These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 31951960)

  • 21. Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti-Proliferative Activity in Lung Cancer Cells.
    Xiao Z; Song S; Chen D; van Merkerk R; van der Wouden PE; Cool RH; Quax WJ; Poelarends GJ; Melgert BN; Dekker FJ
    Angew Chem Int Ed Engl; 2021 Aug; 60(32):17514-17521. PubMed ID: 34018657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors.
    Mao Y; Zhu W; Kong X; Wang Z; Xie H; Ding J; Terrett NK; Shen J; Shen J
    Bioorg Med Chem; 2013 Jun; 21(11):3090-104. PubMed ID: 23602524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
    Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy.
    Zhang H; Zhang Y; Feng Z; Shuai M; Ma X; Wang S; Yu S; Deng R; Luo D; Shi J; Pu C; Li R
    J Med Chem; 2024 Jul; 67(13):10589-10600. PubMed ID: 38889052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
    J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
    Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
    J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.
    Li P; Li B; Yang N; Xu T; Zheng Z
    Expert Opin Ther Pat; 2023; 33(7-8):477-492. PubMed ID: 37873645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological evaluation of Wee1 kinase degraders.
    Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W
    Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
    Zheng M; Huo J; Gu X; Wang Y; Wu C; Zhang Q; Wang W; Liu Y; Liu Y; Zhou X; Chen L; Zhou Y; Li H
    J Med Chem; 2021 Jun; 64(11):7839-7852. PubMed ID: 34038131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective.
    Bao SM; Hu QH; Yang WT; Wang Y; Tong YP; Bao WD
    Anticancer Agents Med Chem; 2019; 19(8):984-991. PubMed ID: 30868964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.
    Abd El Hadi SR; Lasheen DS; Hassan MA; Abouzid KA
    Arch Pharm (Weinheim); 2016 Nov; 349(11):827-847. PubMed ID: 27734525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.
    Su S; Yang Z; Gao H; Yang H; Zhu S; An Z; Wang J; Li Q; Chandarlapaty S; Deng H; Wu W; Rao Y
    J Med Chem; 2019 Aug; 62(16):7575-7582. PubMed ID: 31330105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
    Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
    Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors.
    Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X
    Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.